In the wake of the increase in Current Liabilities in the fourth quarter 2026, Quick Ratio fell to 0.26 below Phibro Animal Health Corporation average.

Within Major Pharmaceutical Preparations industry 414 other companies have achieved higher Quick Ratio than Phibro Animal Health in fourth quarter 2026. While Quick Ratio total ranking in the fourth quarter 2026 has deteriorated compared to the prior quarter from 2411 to 3180.

Explain Quick Ratio?
How much Cash & cash equivalents PAHC�s has?
What are PAHC�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

PAHC Quick Ratio	(Jun 30 2026) Q4	(Mar 31 2026) Q3	(Dec 31 2025) Q2	(Sep 30 2025) Q1	(Jun 30 2025) Q4
Y / Y Current Liabilities Change	104.9 %	3.11 %	33.88 %	58.51 %	31.95 %
Y / Y Cash & cash equivalent Change	6.43 %	10.09 %	-32.78 %	-5.08 %	-32.78 %
Quick Ratio MRQ	0.26	0.51	0.5	0.57	0.5
PAHC's Total Ranking	# 3180	# 2411	# 207	# 2014	# 2012
Seq. Current Liabilities Change	107.56 %	-1.28 %	3.63 %	-3.5 %	4.45 %
Seq. Cash & cash equivalent Change	5.87 %	0.53 %	-9.66 %	10.69 %	9.5 %

Quick Ratio fourth quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 415
Healthcare Sector	# 802
Overall Market	# 3180

Quick Ratio Statistics
High	Average	Low
0.99	0.53	0.11
(Dec 31 2024)

Financial Statements
Phibro Animal Health's Current Liabilities	$ 316 Millions	Visit PAHC's Balance sheet
Phibro Animal Health's Cash & cash equivalent	$ 82 Millions	Visit PAHC's Balance sheet
Source of PAHC's Sales		Visit PAHC's Sales by Geography

Cumulative Phibro Animal Health's Quick Ratio

PAHC's Quick Ratio for the trailling 12 Months

PAHC Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	50.95 %	28.69 %	38.04 %	35.05 %	19.84 %
Y / Y Cash & cash equivalent TTM Growth	-8.55 %	-18.65 %	-25.87 %	-9.68 %	-8.8 %
Quick Ratio TTM	0.42	0.52	0.51	0.61	0.69
Total Ranking TTM	# 4090	# 3222	# 2515	# 1908	# 3170
Seq. Current Liabilities TTM Growth	26.54 %	0.76 %	6.9 %	10.75 %	7.89 %
Seq. Cash & cash equivalent TTM Growth	1.56 %	2.29 %	-10.82 %	-1.3 %	-9.65 %

Quick ratio ranking by company, industry and sector >> Back to PAHC Financial Strength Comparisons >> Go to Compare PAHC Quick Ratio to its Competitors

On the trailing twelve months basis Due to in Current Liabilities in the Q4 2026 to $316.47 millions, cumulative Quick Ratio decreased to 0.42 above the PAHC average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 442 other companies have achieved higher Quick Ratio than Phibro Animal Health. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2026 from 3222 to 4090.

Explain Quick Ratio?
How much Cash & cash equivalents PAHC�s has?
What are PAHC�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 443
Healthcare Sector	# 908
Within the Market	# 4090

trailing twelve months Quick Ratio Statistics
High	Average	Low
0.49	0.29	0.12
(Dec 31 2017)		(Dec 31 2014)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Heron Therapeutics Inc	0.70	$ 64.643 Millions	$ 92.145 Millions
Amphastar Pharmaceuticals Inc	0.70	$ 331.903 Millions	$ 476.848 Millions
Axsome Therapeutics Inc	0.69	$ 319.850 Millions	$ 460.446 Millions
Zentalis Pharmaceuticals Inc	0.66	$ 24.783 Millions	$ 37.709 Millions
Pfizer Inc	0.64	$ 20,881.000 Millions	$ 32,646.000 Millions
Enanta Pharmaceuticals Inc	0.62	$ 33.419 Millions	$ 54.166 Millions
60 Degrees Pharmaceuticals Inc	0.61	$ 1.023 Millions	$ 1.685 Millions
Eton Pharmaceuticals Inc	0.59	$ 26.845 Millions	$ 45.124 Millions
Kura Oncology Inc	0.59	$ 70.242 Millions	$ 118.193 Millions
Allarity Therapeutics Inc	0.59	$ 16.982 Millions	$ 28.579 Millions
Bristol myers Squibb Company	0.59	$ 11,067.000 Millions	$ 18,659.000 Millions
Prestige Consumer Healthcare Inc	0.58	$ 89.127 Millions	$ 153.806 Millions
Biora Therapeutics Inc	0.57	$ 21.906 Millions	$ 38.687 Millions
Matinas Biopharma Holdings Inc	0.56	$ 0.761 Millions	$ 1.350 Millions
Karyopharm Therapeutics Inc	0.56	$ 75.225 Millions	$ 134.233 Millions
Journey Medical Corp	0.56	$ 25.643 Millions	$ 45.770 Millions
Nektar Therapeutics	0.55	$ 39.267 Millions	$ 70.985 Millions
Supernus Pharmaceuticals inc	0.52	$ 180.145 Millions	$ 347.378 Millions
Citius Oncology Inc	0.50	$ 16.564 Millions	$ 33.152 Millions
Verrica Pharmaceuticals Inc	0.50	$ 11.198 Millions	$ 22.442 Millions
Aytu Biopharma Inc	0.48	$ 26.308 Millions	$ 54.659 Millions
Jupiter Neurosciences Inc	0.47	$ 1.522 Millions	$ 3.251 Millions
Aeon Biopharma inc	0.47	$ 3.431 Millions	$ 7.342 Millions
Evolus Inc	0.46	$ 45.170 Millions	$ 98.731 Millions
Biomarin Pharmaceutical Inc	0.45	$ 874.005 Millions	$ 1,927.164 Millions
Pds Biotechnology Corp	0.45	$ 5.596 Millions	$ 12.377 Millions
Biofrontera Inc	0.44	$ 4.659 Millions	$ 10.541 Millions
Beyondspring Inc	0.43	$ 10.361 Millions	$ 23.834 Millions
Organon and Co	0.43	$ 1,132.000 Millions	$ 2,616.000 Millions
Gossamer Bio Inc	0.41	$ 57.026 Millions	$ 137.783 Millions

Date modified: 2026-09-08T15:22:21+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.